Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program

References

• Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2017. Atlanta (GA): U.S. Department of Health and Human Services; 2017. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
   Google Scholar
• Centers for Disease Control and Prevention. At a glance 2016. Diabetes: working to reverse the epidemic. Atlanta (GA): U.S. Department of Health and Human Services; 2016. Available from: https://www.cdc.gov/chronicdisease/resources/publications/aag/pdf/2016/diabetes-aag.pdf
   Google Scholar
• Schneiderman N, Llabre M, Cowie CC, et al. Prevalence of diabetes among Hispanics/Latinos from diverse backgrounds: the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Diabetes Care. 2014;37:2233–2239.
   PubMed Web of Science ®Google Scholar
• Haffner SM, Hazuda HP, Mitchell BD, et al. Increased incidence of type II diabetes mellitus in Mexican Americans. Diabetes Care. 1991;14:102–108.
   PubMed Web of Science ®Google Scholar
• Tucker KL, Bermudez OI, Castaneda C. Type 2 diabetes is prevalent and poorly controlled among Hispanic elders of Caribbean origin. Am J Public Health. 2000;90:1288–1293.
   PubMed Web of Science ®Google Scholar
• Kirk JK, Passmore LV, Bell RA, et al. Disparities in A1C levels between Hispanic and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care. 2008;31:240–246.
   PubMed Web of Science ®Google Scholar
• Kirk JK, Bell RA, Bertoni AG, et al. Ethnic disparities: control of glycemia, blood pressure, and LDL cholesterol among US adults with type 2 diabetes. Ann Pharmacother. 2005;39:1489–1501.
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Nasser SA. Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31:913–923.
   PubMed Web of Science ®Google Scholar
• Rodríguez JE, Campbell KM. Racial and ethnic disparities in prevalence and care of patients with type 2 diabetes. Clin Diabetes. 2017;35:66–70.
   PubMedGoogle Scholar
• Campbell JA, Walker RJ, Smalls BL, et al. Glucose control in diabetes: the impact of racial differences on monitoring and outcomes. Endocrine. 2012;42:471–482.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–165.
   PubMed Web of Science ®Google Scholar
• Matthews JE, Stewart MW, De Boever EH, et al.; Albiglutide Study Group. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:4810–4817.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Reusch J, Bush M, et al.; Albiglutide Study Group. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009;32:1880–1886.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Stewart MW. Albiglutide. Glucagon-like peptide GLP-1 receptor agonist, treatment of type 2 diabetes. Drugs Fut. 2010;35:701.
   Web of Science ®Google Scholar
• Reusch J, Stewart MW, Perkins CM, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Obes Metab. 2014;16:1257–1264.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Stewart MW, Perkins C, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia. 2016;59:266–274.
   PubMed Web of Science ®Google Scholar
• Ahrén B, Johnson SL, Stewart M, et al.; HARMONY 3 Study Group. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37:2141–2148.
   PubMed Web of Science ®Google Scholar
• Weissman PN, Carr MC, Ye J, et al. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia. 2014;57:2475–2484.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Fonseca VA, Gross JL, et al.; Harmony 6 Study Group. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care. 2014;37:2317–2325.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck MA, Barnett AH, et al.; HARMONY 7 Study Group. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289–297.
   PubMed Web of Science ®Google Scholar
• Home PD, Shamanna P, Stewart M, et al. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes Metab. 2015;17:179–187.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Carr MC, Stewart M, et al. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014;37:2723–2730.
   PubMed Web of Science ®Google Scholar
• Pencek R, Blickensderfer A, Li Y, et al. Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations. Int J Clin Pract. 2012;66:1021–1032.
   PubMed Web of Science ®Google Scholar
• Sun F, Chai S, Yu K, et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Technol Ther. 2015;17(1):35–42.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Mallory JM, Wilson TH, et al. Gastrointestinal safety across the albiglutide development programme. Diabetes Obes Metab. 2016;18:930–935.
   PubMed Web of Science ®Google Scholar
• BYETTA® (exenatide) Injection [prescribing information]. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2015. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021773s040lbl.pdf
   Google Scholar
• BYDUREON™ (exenatide extended-release) for injectable suspension [prescribing information]. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2015. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022200s015s016s017s018lbl.pdf
   Google Scholar
• VICTOZA® (liraglutide) injection, for subcutaneous use [prescribing information]. Bagsvaerd (Denmark): Novo Nordisk A/S; 2016. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022341s025lbl.pdf
   Google Scholar